RZONF.US Rize Oncology Inc.
- Market cap
- USD 32.3K
- P/E
- -
- P/B
- 0.03x
- ROE
- -49.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is RZONF.US undervalued?
Graham numberThe Graham number of Rize Oncology Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rize Oncology Inc. fundamental analysis
No fundamental analysis for Rize Oncology Inc. yet.
Rize Oncology Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rize Oncology Inc.
Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, other types of cancers, and certain proliferative diseases. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 an…
Full company profileRize Oncology Inc. financial statements
Rize Oncology Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.64M | -1.72M | -747K | -589K |
| EBITDA | -1.64M | -1.72M | -747K | -589K |
| Net Income | -1.64M | -1.72M | -688K | -551K |
| EPS | -0.04 | -0.04 | -0.02 | -0.01 |
| Balance Sheet | ||||
| Total Assets | 370K | 1.94M | 1.41M | 1.19M |
| Total Liabilities | 213K | 87.4K | 38.6K | 83.1K |
| Shareholders' Equity | 157K | 1.86M | 1.37M | 1.11M |
| Cash & Short-term Investments | 180K | 1.80M | 1.36M | 1.16M |
| Cash Flow | ||||
| Operating Cash Flow | -740K | -1.18M | -465K | -466K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -740K | -1.18M | -465K | -466K |
| Ratios | ||||
| ROE | -1,041.6% | -92.4% | -50.2% | -49.7% |
| ROA | -442.1% | -88.2% | -48.8% | -46.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Rize Oncology Inc. dividends
Rize Oncology Inc. has not paid dividends in the last 4 fiscal years.
Who owns Rize Oncology Inc.
- Insiders 77.44%
- Institutions 0.00%
- Public & others 22.56%
- Shares outstanding 80.7M
- Free float 15.5M
Rize Oncology Inc. company profile
- Company name
- Rize Oncology Inc.
- Ticker
- RZONF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 301 ? 1665 Ellis Street, Kelowna, BC, Canada, V1Y 2B3
- Phone
- 514 796 2640
- Website
- rizeoncology.com
About Rize Oncology Inc.
Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, other types of cancers, and certain proliferative diseases. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada.
Rize Oncology Inc. management
3- Mr. P. Gage Jull B.Sc., C.F.A., M.B.A., P.Eng.Interim CEO & Director · born 1960
- Mr. Jim O'NeillCFO & Corporate Secretary
- Dr. John M. Rothman Ph.D.Chief Scientific Officer · born 1948